Photonics21 backs preventive medicine
Professor Jürgen Popp says Europe must shift from reactive healthcare to predictive, photonics-enabled prevention to improve patient outcomes and reduce mounting healthcare costs.
Europe must fundamentally rethink its healthcare model by moving from treating disease to preventing it through photonics and artificial intelligence, according to Professor Jürgen Popp, a leading European scientist and advocate for photonics-driven healthcare innovation.
Speaking as part of the Photonics21 Health Grand Challenge, Popp argued that Europe’s ageing population and rising healthcare costs make the current reactive approach unsustainable.
Instead, he called for the adoption of predictive, preventive, personalised and participatory (P4) medicine, where diseases are detected at their earliest biological stages before symptoms appear.
Photonics technologies, including advanced optical diagnostics and molecular sensing, are expected to play a central role in this transition.
By analysing biological samples such as blood and saliva, combined with AI-driven data analysis, these technologies could provide continuous insights into an individual’s health and enable earlier intervention.
Popp also highlighted the long-term vision of developing Personalised Optical Digital Twins—dynamic virtual models built from optical, molecular, clinical and lifestyle data that evolve alongside each individual.
Such digital representations could help identify emerging health risks, support clinical decision-making and shift healthcare from episodic treatment to continuous health monitoring.
According to Photonics21, Europe is well positioned to lead this transformation thanks to its strengths in photonics, artificial intelligence, medical technologies and clinical research.
The organisation believes integrating these capabilities into a unified innovation ecosystem could both improve healthcare outcomes and strengthen Europe's competitiveness in medical technology.
"The scientific foundations are in place," said Popp. "The challenge now is how quickly Europe can integrate, validate and scale them to fundamentally change how we maintain health and manage disease."
